BBH - VanEck Vectors Biotech ETF

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
116.95
-1.97 (-1.66%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close118.92
Open117.46
Bid114.89 x 800
Ask121.03 x 1200
Day's Range116.73 - 118.00
52 Week Range111.36 - 136.84
Volume8,939
Avg. Volume15,095
Net Assets428.32M
NAV124.28
PE Ratio (TTM)N/A
Yield0.55%
YTD Return-0.22%
Beta (3Y Monthly)1.50
Expense Ratio (net)0.35%
Inception Date2011-12-20
Trade prices are not sourced from all markets
  • Business Wire29 days ago

    VanEck Announces Preliminary Yearend Distribution Estimates for VanEck Vectors Equity ETFs

    VanEck announced today preliminary yearend distribution estimates for its VanEck Vectors® equity exchange-traded funds.

  • Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings
    Market Realist2 months ago

    Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings

    Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion, compared to estimates for EPS of $4.03 on revenues of $3.88 billion during the third quarter of 2018.

  • Recommendations for Shire as of October 30
    Market Realist2 months ago

    Recommendations for Shire as of October 30

    There are 11 analysts tracking Shire stock as of October 30. Four of them are recommending a “strong buy,” five are recommending a “buy,” and two are recommending a “hold.” None of them have recommended a “sell.” The changes in analysts’ estimates and recommendations are based on changing trends in the stock and the company’s performance.

  • What Analysts Recommend for Incyte ahead of Q3 Earnings
    Market Realist2 months ago

    What Analysts Recommend for Incyte ahead of Q3 Earnings

    Wall Street analysts estimate Incyte’s (INCY) revenues will increase by ~17.7% to $449.2 million during the third quarter of 2018 compared to revenues of $381.5 million during the third quarter of 2017. Also, the earnings per share are estimated to be $0.40 for the third quarter of 2018 as compared to earnings per share of $0.08 for the third quarter of 2017. Incyte stock has fallen nearly 46.6% over the last 12 months and decreased by ~35.7% in 2018 year-to-date.

  • Amgen: Expect Nearly Flat Revenues in Q3
    Market Realist2 months ago

    Amgen: Expect Nearly Flat Revenues in Q3

    As we discussed earlier, analysts expect Amgen (AMGN) to report nearly flat revenues at $5.77 billion during the third quarter. Amgen’s product portfolio includes human therapeutics.

  • Allergan’s Q3 2018 Estimates: Revenue Decline Expected
    Market Realist2 months ago

    Allergan’s Q3 2018 Estimates: Revenue Decline Expected

    Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decrease 3.8% to $3.88 billion. Allergan has classified its business operations into three business segments: US Specialized Therapeutics US General Medicine International

  • Biogen: Analysts’ Recommendations on October 19
    Market Realist2 months ago

    Biogen: Analysts’ Recommendations on October 19

    Wall Street analysts expect Biogen’s (BIIB) third-quarter revenues to increase ~8.2% to $3.33 billion—compared to its revenues of $3.07 million during the third quarter of 2017. Biogen’s stock price has decreased nearly 4.1% in the last 12 months. Analysts’ recommendations show a 12-month target price of $390.88 per share—compared to the last price of $330.15 per share as of October 18.

  • Business Wire2 months ago

    VanEck Launches ESPO, ETF Focused on Fast Growing Video Game and eSports Industry

    ESPO provides targeted exposure to “the future of sports”: video game and related software developers, streaming services, companies involved in eSports events, and more

  • Analysts Are Mostly Positive on Neurocrine Biosciences
    Market Realist2 months ago

    Analysts Are Mostly Positive on Neurocrine Biosciences

    Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.

  • Allergan’s Stock Performance and Estimates for Q3 2018
    Market Realist2 months ago

    Allergan’s Stock Performance and Estimates for Q3 2018

    Allergan’s (AGN) product portfolio includes generic pharmaceutical products and specialty pharmaceutical products. The company’s business comprises three segments—US General Medicines, US Specialized Therapeutics, and International. The chart below compares Allergan’s revenues and EPS since the first quarter of 2017, as well as its estimates for the third quarter.

  • Ionis Pharmaceuticals’ Valuations on September 28
    Market Realist2 months ago

    Ionis Pharmaceuticals’ Valuations on September 28

    Ionis Pharmaceuticals (IONS) develops drugs for life-threatening diseases, and it commercializes the approved products in collaboration with other pharmaceutical companies. Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in YoY (year-over-year) revenues compared to the second quarter of 2017.

  • Allergan’s Developments in September
    Market Realist3 months ago

    Allergan’s Developments in September

    Allergan (AGN) is a specialty pharmaceutical company focused on organic as well as inorganic growth methods. The chart below highlights several recent developments for Allergan.

  • Estimates and Recommendations for Shire on September 19
    Market Realist3 months ago

    Estimates and Recommendations for Shire on September 19

    Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017. Analysts expect Shire’s net adjusted income to increase to $4.68 billion in 2018 compared to its net adjusted income of $4.60 billion in 2017. Shire’s stock price has risen nearly 15.4% in the last 12 months, and it’s risen ~15.7% year-to-date in 2018.

  • Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
    Market Realist3 months ago

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.

  • A Look at Incyte’s Valuation on August 22
    Market Realist4 months ago

    A Look at Incyte’s Valuation on August 22

    Incyte (INCY), a biopharmaceutical company, is focused on the discovery, development, and commercialization of various products to cater to unmet medical needs in oncology and the treatment of other diseases.

  • Examining Amgen’s Revenue Trend in Q2 2018
    Market Realist4 months ago

    Examining Amgen’s Revenue Trend in Q2 2018

    As we discussed earlier, Amgen (AMGN) reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017. Amgen surpassed analysts’ estimates for EPS and revenue in the second quarter, reporting non-GAAP (generally accepted accounting principles) EPS of $3.83 on revenue of ~$6.1 billion compared to the estimate of $3.54 on revenue of $5.7 billion.

  • Considering Allergan’s Q2 2018 Revenue Trend
    Market Realist4 months ago

    Considering Allergan’s Q2 2018 Revenue Trend

    As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter compared to $4.0 billion in the second quarter of 2017.

  • What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?
    Market Realist4 months ago

    What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

    Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases. Ionis commercializes the approved products in collaboration with other pharmaceuticals companies. Ionis reported revenues of $118 million in Q2 2018, a 5% increase in year-over-year (or YoY) revenues as compared to the second quarter of 2017.

  • Bluebird Bio Misses Analysts’ Estimates in Q2 2018
    Market Realist4 months ago

    Bluebird Bio Misses Analysts’ Estimates in Q2 2018

    Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates. It reported EPS of -$2.91 on revenue of $7.8 million during Q2 2018, compared with -$2.35 on revenue of $9.6 million. The chart below compares the company’s revenue and EPS since Q1 2017.

  • Investopedia4 months ago

    Adding Biotech ETFs to Your Portfolio

    As the name suggests, the biotechnology sector combines elements of biology with the development and manufacturing of products and business ventures. Both of these components have experienced unbelievable advances in recent decades, making the biotechnology area an exciting one for investors. Best of all, biotechnology's impact covers an ever-expanding range of tangential fields and areas, including medicine, pharmaceuticals, the environment, food, genetics and much more.

  • What Analysts Recommend for Bluebird Bio Stock
    Market Realist5 months ago

    What Analysts Recommend for Bluebird Bio Stock

    As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter. Of the 21 analysts tracking Bluebird Bio, five recommend “strong buy,” nine recommend “buy,” six recommend “hold,” and one recommends “sell.” 

  • Shire’s Q2 2018 Earnings Beat Analyst Estimates
    Market Realist5 months ago

    Shire’s Q2 2018 Earnings Beat Analyst Estimates

    Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018, compared to estimates for EPS of $3.67 on revenues of $3.8 billion.

  • ETF Trends5 months ago

    Biotech ETFs Climb on Biogen’s Promising Clinical Trial

    Biotech ETFs rallied Friday after Biogen (NasdaqGS: BIIB) announced successful results from its Alzheimer’s drug trial. On Friday, large-cap biotechnology sector ETFs lead the charge. The iShares Nasdaq ...

  • Top-Ranked Sector ETFs to Buy for Q3
    Zacks6 months ago

    Top-Ranked Sector ETFs to Buy for Q3

    These sector ETFs have a Zacks Rank #1 or 2 and are likely to outperform ahead.

  • What Drove Ionis’s Revenue in Q1
    Market Realist7 months ago

    What Drove Ionis’s Revenue in Q1

    In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million, as shown in the chart below. Ionis’s revenue sources include commercial revenue from Spinraza royalties and other licensing and royalty revenue, as well as research and development revenue under collaborative agreements. Spinraza (nusinersen), approved for the treatment of pediatric and adult patients with spinal muscular atrophy, was developed in collaboration with Biogen (BIIB), which holds Spinraza’s development, manufacturing, and commercializing licenses. Kynamro injections, approved by the FDA for the treatment of homozygous familial hypercholesterolemia, is developed and commercialized by Kastle Therapeutics, a Sanofi (SNY) subsidiary.